Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner

Molecular and Cellular Biology

Volumn 28, Issue 7, 2008, Pages 2235-2243

  Bailey, Caleb M ^a   Abbott, Daniel E ^a   Margaryan, Naira V ^a   Khalkhali Ellis, Zhila ^a,b   Hendrix, Mary J C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON REGULATORY FACTOR 6; MASPIN; PROTEASOME;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; MAMMARY GLAND; PREGNANCY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; G0 PHASE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON REGULATORY FACTORS; LACTATION; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PREGNANCY; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; SERPINS;

EID: 41149129204     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01866-07     Document Type: Article

References (34)

1. Aziz, F., A. J. van Wijnen, J. L. Stein, and G. S. Stein. 1998. HiNF-D (CDP-cut/CDC2/cyclin A/pRB-complex) influences the timing of IRF-2-dependent cell cycle activation of human histone H4 gene transcription at the G1/S phase transition. J. Cell. Physiol. 177:453-464.
2. Bailey, C. M., Z. Khalkhali-Ellis, S. Kondo, N. V. Margaryan, R. E. Seftor, W. W. Wheaton, S. Amir, M. R. Pins, B. C. Schutte, and M. J. Hendrix. 2005. Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J. Biol. Chem. 280:34210-34217.
3. Barnes, B. J., M. J. Kellum, K. E. Pinder, J. A. Frisancho, and P. M. Pitha. 2003. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 63:6424-6431.
4. Brandeis, M., and T. Hunt. 1996. The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase. EMBO J. 15:5280-5289.
5. Chen, D., M. S. Chen, Q. C. Cui, H. Yang, and Q. P. Dou. 2007. Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells. Front. Biosci. 12:1935-1945.
6. Chen, D., K. G. Daniel, M. S. Chen, D. J. Kuhn, K. R. Landis-Piwowar, and Q. P. Dou. 2005. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol. 69:1421-1432.
7. Chen, E. I., L. Florens, F. T. Axelrod, E. Monosov, C. F. Barbas III, J. R. Yates III, B. Felding-Habermann, and J. W. Smith. 2005. Maspin alters the carcinoma proteome. FASEB J. 19:1123-1124.
8. Debnath, J., S. K. Muthuswamy, and J. S. Brugge. 2003. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30:256-268.
9. Duguay, D., F. Mercier, J. Stagg, D. Martineau, J. Bramson, M. Servant, R. Lin, J. Galipeau, and J. Hiscott. 2002. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res. 62:5148-5152.
10. Ford, H. L., E. Landesman-Bollag, C. S. Dacwag, P. T. Stukenberg, A. B. Pardee, and D. C. Seldin. 2000. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J. Biol. Chem. 275:22245-22254.
11. Hu, G., M. E. Mancl, and B. J. Barnes. 2005. Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res. 65:7403-7412.
12. Ingraham, C. R., A. Kinoshita, S. Kondo, B. Yang, S. Sajan, K. J. Trout, M. I. Malik, M. Dunnwald, S. L. Goudy, M. Lovett, J. C. Murray, and B. C. Schutte. 2006. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat. Genet. 38:1335-1340.
13. Kirschmann, D. A., E. A. Seftor, S. F. Fong, D. R. Nieva, C. M. Sullivan, E. M. Edwards, P. Sommer, K. Csiszar, and M. J. Hendrix. 2002. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 62:4478-4483.
14. Kondo, S., B. C. Schutte, R. J. Richardson, B. C. Bjork, A. S. Knight, Y. Watanabe, E. Howard, R. L. de Lima, S. Daack-Hirsch, A. Sander, D. M. McDonald-McGinn, E. H. Zackai, E. J. Lammer, A. S. Aylsworth, H. H. Ardinger, A. C. Lidral, B. R. Pober, L. Moreno, M. Arcos-Burgos, C. Valencia, C. Houdayer, M. Bahuau, D. Moretti-Ferreira, A. Richieri-Costa, M. J. Dixon, and J. C. Murray. 2002. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat. Genet. 32:285-289.
15. Kroger, A., A. Dallugge, S. Kirchhoff, and H. Hauser. 2003. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo. Oncogene 22:1045-1056.
16. Kuo, M. L., and N. C. Yang. 1995. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem. Biophys. Res. Commun. 212:767-775.
17. Li, X., D. Chen, S. Yin, Y. Meng, H. Yang, K. R. Landis-Piwowar, Y. Li, F. H. Sarkar, G. P. Reddy, Q. P. Dou, and S. Sheng. 2007. Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. J. Cell. Physiol. 212:298-306.
18. Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-2996.
19. Ma, C., S. J. Mandrekar, S. R. Alberts, G. A. Croghan, A. Jatoi, J. M. Reid, L. J. Hanson, L. Bruzek, A. D. Tan, H. C. Pitot, C. Erlichman, J. J. Wright, and A. A. Adjei. 2007. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother. Pharmacol. 59:207-215.
20. Marie, I., E. Smith, A. Prakash, and D. E. Levy. 2000. Phosphorylation-induced dimerization of interferon regulatory factor 7 unmasks DNA binding and a bipartite transactivation domain. Mol. Cell. Biol. 20:8803-8814.
21. Moriyama, Y., S. Nishiguchi, A. Tamori, N. Koh, Y. Yano, S. Kubo, K. Hirohashi, and S. Otani. 2001. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma. Clin. Cancer Res. 7:1293-1298.
22. Nakagawa, K., and H. Yokosawa. 2000. Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. Eur. J. Biochem. 267:1680-1686.
23. Odero-Marah, V. A., Z. Khalkhali-Ellis, J. Chunthapong, S. Amir, R. E. Seftor, E. A. Seftor, and M. J. Hendrix. 2003. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol. Ther. 2:398-403.
24. Paz, S., Q. Sun, P. Nakhaei, R. Romieu-Mourez, D. Goubau, I. Julkunen, R. Lin, and J. Hiscott. 2006. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell. Mol. Biol. (Noisy-le-Grand) 52:17-28.
25. Pham, N. A., A. Morrison, J. Schwock, S. Aviel-Ronen, V. Iakovlev, M. S. Tsao, J. Ho, and D. W. Hedley. 2007. Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn. Pathol. 2:8.
26. Richardson, R. J., J. Dixon, S. Malhotra, M. J. Hardman, L. Knowles, R. P. Boot-Handford, P. Shore, A. Whitmarsh, and M. J. Dixon. 2006. Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat. Genet. 38:1329-1334.
27. Saitoh, T., A. Tun-Kyi, A. Ryo, M. Yamamoto, G. Finn, T. Fujita, S. Akira, N. Yamamoto, K. P. Lu, and S. Yamaoka. 2006. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat. Immunol. 7:598-605.
28. Senderowicz, A. M., and E. A. Sausville. 2000. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92:376-387.
29. Stanford, B. L., and S. D. Zondor. 2003. Bortezomib treatment for multiple myeloma. Ann. Pharmacother. 37:1825-1830.
30. Takigawa, T., and K. Shiota. 2004. Terminal differentiation of palatal medial edge epithelial cells in vitro is not necessarily dependent on palatal shelf contact and midline epithelial seam formation. Int. J. Dev. Biol. 48:307-317.
31. Tanaka, N., M. Ishihara, M. Kitagawa, H. Harada, T. Kimura, T. Matsuyama, M. S. Lamphier, S. Aizawa, T. W. Mak, and T. Taniguchi. 1994. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77:829-839.
32. Way, T. D., M. C. Kao, and J. K. Lin. 2004. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem. 279:4479-4489.
33. Xiong, H., H. Li, H. J. Kong, Y. Chen, J. Zhao, S. Xiong, B. Huang, H. Gu, L. Mayer, K. Ozato, and J. C. Unkeless. 2005. Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression. J. Biol. Chem. 280:23531-23539.
34. Zhang, M., D. Magit, F. Botteri, H. Y. Shi, K. He, M. Li, P. Furth, and R. Sager. 1999. Maspin plays an important role in mammary gland development. Dev. Biol. 215:278-287.